Tirzepatide cuts the risk of major adverse cardiovascular events by 32% compared to sitagliptin in adults with Type 2 diabetes and established atherosclerotic cardiovascular disease, according to a population based cohort study published in the BMJ by N. Krüger et al. The real-world data analysis tracked 52,971 patients in the USA over a one-year period, revealing clinical benefits that extend beyond standard blood sugar control and weight management.
Cardiovascular Risk Reduction Data in Type 2 Diabetes
Researchers evaluated 35,353 patients who initiated tirzepatide against a control group of 17,618 patients treated with a sitagliptin placebo proxy. After one year, exactly 2.9% of individuals taking tirzepatide experienced a major adverse cardiovascular event (MACE). By comparison, 4.4% of the patients taking sitagliptin faced the same outcomes.
When evaluating real-world observational data, medical researchers look at the number needed to treat to understand practical impact. In this study, for every 70 people treated with tirzepatide instead of sitagliptin, one additional major cardiovascular event was prevented.
When breaking down individual cardiovascular events, investigators noted that tirzepatide linked to a lower risk of heart attack. However, the study data showed no clear difference in the risk of ischaemic stroke between the two groups, according to the published findings.
Lower Hospitalization Rates for Infections
Beyond cardiac outcomes, the data revealed a drop in severe infections among patients receiving the dual incretin agonist of glucose-dependent insulinotropic peptide and glucagon-like peptide 1 receptors. Tirzepatide treatment was associated with fewer infections requiring hospital treatment.
The statistical analysis showed that for every 48 people treated with tirzepatide instead of sitagliptin, one hospitalisation for infection was prevented. Furthermore, the cohort taking tirzepatide experienced fewer deaths caused by infection, alongside a reduction in overall mortality rates during the study timeframe.
Did you know? Dual-action incretin therapies target both GIP and GLP-1 receptors simultaneously, which researchers continue to study for pleiotropic effects beyond metabolic regulation.
Methodology and Real-World Evidence Limitations
To verify that these health outcomes were not anomalies, the study authors examined unrelated health conditions as a way of checking whether the results could be explained by other factors. They found no meaningful link between tirzepatide and those conditions, which strengthened confidence in the primary findings.
Since the research relied on observational patient information instead of a randomized clinical trial, the investigators pointed out that the data cannot establish a direct causal relationship between tirzepatide and these health gains. At the same time, these conclusions add important findings to the expanding pool of research supporting GLP-1 medications in lowering heart disease risks while aiding weight loss among individuals with established cardiovascular risk and Type 2 diabetes, as well as those suffering from obesity and heart disease without diabetes.
Frequently Asked Questions
What is tirzepatide?
Acting upon both glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1) receptors, tirzepatide functions as a dual incretin agonist.
How much did tirzepatide reduce cardiovascular risk?
According to the BMJ study, tirzepatide reduced the risk by 32% compared to sitagliptin.
Does this study prove direct causation?
Stay Informed on Clinical Research
Explore our latest coverage on pharmaceutical studies, metabolic health trends, and peer-reviewed medical data.
Worth a look